Outcomes of combined ipilimumab/nivolumab in metastatic uveal melanoma: A prevalence meta-analysis. Autoantibodies as potential biomarkers of immune-related adverse events in patients with advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results